Futura Medical PLC Futura to Update on MED3000 at Investor Seminar (0384F)
05 Marzo 2020 - 1:00AM
UK Regulatory
TIDMFUM
RNS Number : 0384F
Futura Medical PLC
05 March 2020
05 March 2020
Futura Medical to Present "FM57" Clinical Data and Provide
Update on MED3000 at Investor Seminar in March 2020
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a
pharmaceutical company developing a portfolio of innovative
products based on its on its proprietary, transdermal technology
DermaSys(R) and currently focused on sexual health and pain,
announces plans to host an Investor Seminar in London for analysts
and institutional investors on Thursday, 26 March 2020.
The seminar follows an extensive internal evaluation of the
clinical data from the Phase 3 study ("FM57") announced on 10
December 2019. Ken James, Executive Director and Head of R&D
will present the Company's ongoing research and analysis of the
FM57 and MED3000.
James Barder, Chief Executive Officer of Futura Medical, said:
"FM57 results demonstrate that MED3000 is a highly effective, safe
and differentiated therapy for ED. After an extensive internal
evaluation of the FM57 clinical data, we are pleased to be able to
share our ongoing clinical and literature-based research and
analysis, examining MED3000 efficacy and modes of action in ED. In
addition, following positive interactions with an EU Notified Body
announced in February 2020, we look forward to providing the market
with further updates regarding the formal proceedings of MED3000 to
be approved as a medical for treatment of ED."
The seminar will also feature a presentation from Professor
David Ralph, world leading expert in erectile dysfunction and male
infertility and member of the Futura European KOL Advisory Panel,
providing an insight into the ED market.
Professor David Ralph is a leading Consultant in the field of
Andrology. He practices both privately and on the NHS, and holds a
senior consultant post at the University College London Hospital.
He is a Professor at the Cranfield University and is a senior
lecturer at the Institute of Urology, London. Professor David's
main areas of expertise are penile implants, total genital
reconstruction, Peyronie's disease and male infertility. He is
internationally recognised for his work.
For further information on the Investor Seminar, or to register
your interest, please contact Optimum Strategic Communications at
futuramedical@optimumcomms.com. Further information will be made
available in March 2020.
The event will be webcast and will be made available on the
investor section of website shortly after the event.
-ENDS-
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Bidhi Bhoma/ Euan Brown/ Kane Collings
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCQZLFBBXLFBBQ
(END) Dow Jones Newswires
March 05, 2020 02:00 ET (07:00 GMT)
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024